Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon A Jones

Showing results (141-150 of 259) with videos related to

Pageof 26
Sort By:
The American Journal of Pathology|September 25, 2016
Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic DiseaseWilliam V Perks, Ravinder K Singh, Gareth W Jones, et al.
Diabetes|April 3, 2019
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune ComorbiditiesFlorian Wiede, Thomas C Brodnicki, Pei Kee Goh, et al.
Science (New York, N.Y.)|April 26, 2014
The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewalMarcela Rosas, Luke C Davies, Peter J Giles, et al.
Orphanet Journal of Rare Diseases|June 28, 2017
Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type IIIArunabha Ghosh, Elsa Shapiro, Stewart Rust, et al.
Science Immunology|July 19, 2020
T<sub>H</sub>17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identityStacey N Harbour, Daniel F DiToro, Steven J Witte, et al.
Molecular Genetics and Metabolism|June 8, 2015
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiencyMelissa P Wasserstein, Simon A Jones, Handrean Soran, et al.
Clinical Genetics|June 14, 2019
Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I RegistryLorne A Clarke, Roberto Giugliani, Nathalie Guffon, et al.
The Journal of Biological Chemistry|October 13, 2011
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptorChristoph Garbers, Wolfgang Thaiss, Gareth W Jones, et al.
Science Signaling|August 18, 2021
Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T<sub>H</sub>17 cell expansionDenise Heise, Alicia Derrac Soria, Selina Hansen, et al.
Orphanet Journal of Rare Diseases|December 14, 2022
Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year resultsGeorge A Diaz, Roberto Giugliani, Nathalie Guffon, et al.
Pageof 26

Showing results (141-150 of 259) with videos related to

Sort By:
Pageof 26
The American Journal of Pathology|September 25, 2016
Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic DiseaseWilliam V Perks, Ravinder K Singh, Gareth W Jones, et al.
Diabetes|April 3, 2019
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune ComorbiditiesFlorian Wiede, Thomas C Brodnicki, Pei Kee Goh, et al.
Science (New York, N.Y.)|April 26, 2014
The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewalMarcela Rosas, Luke C Davies, Peter J Giles, et al.
Orphanet Journal of Rare Diseases|June 28, 2017
Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type IIIArunabha Ghosh, Elsa Shapiro, Stewart Rust, et al.
Science Immunology|July 19, 2020
T<sub>H</sub>17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identityStacey N Harbour, Daniel F DiToro, Steven J Witte, et al.
Molecular Genetics and Metabolism|June 8, 2015
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiencyMelissa P Wasserstein, Simon A Jones, Handrean Soran, et al.
Clinical Genetics|June 14, 2019
Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I RegistryLorne A Clarke, Roberto Giugliani, Nathalie Guffon, et al.
The Journal of Biological Chemistry|October 13, 2011
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptorChristoph Garbers, Wolfgang Thaiss, Gareth W Jones, et al.
Science Signaling|August 18, 2021
Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T<sub>H</sub>17 cell expansionDenise Heise, Alicia Derrac Soria, Selina Hansen, et al.
Orphanet Journal of Rare Diseases|December 14, 2022
Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year resultsGeorge A Diaz, Roberto Giugliani, Nathalie Guffon, et al.
Pageof 26